Norges Bank’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Norges Bank’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-21,439	Closed	-$129K	–	2124
2019 Q2	$129K	Hold	21,439	–	–	﹤0.01%	2085
2019 Q1	$287K	Sell	21,439 -106,837	-83%	-$1.22M	﹤0.01%	2091
2018 Q4	$1.19M	Sell	128,276 -175,624	-58%	-$2.09M	﹤0.01%	2033
2018 Q3	$4.23M	Hold	303,900	–	–	﹤0.01%	1984
2018 Q2	$4.8M	Buy	303,900 +52,554	+21%	+$917K	﹤0.01%	1958
2018 Q1	$4.32M	Buy	251,346 +13,646	+6%	+$266K	﹤0.01%	1914
2017 Q4	$5.21M	Hold	237,700	–	–	﹤0.01%	1865
2017 Q3	$9.72M	Buy	237,700 +70,798	+42%	+$2.22M	﹤0.01%	1742
2017 Q2	$5.03M	Sell	166,902 -52,139	-24%	-$1.63M	﹤0.01%	1882
2017 Q1	$7.92M	Buy	219,041 +77,758	+55%	+$3.43M	﹤0.01%	1803
2016 Q4	$7.08M	Buy	+141,283	New	+$7.42M	﹤0.01%	1796

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's FPRX Position: Q3 2019 in Review

Norges Bank sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2019, closing a stake of 21,439 shares — an estimated $129K sold.

Norges Bank first reported a position in FPRX in Q4 2016 and held it in 11 quarters. The position peaked at $9.72M in Q3 2017. 103 funds tracked by Wall St. Rank hold FPRX as of Q3 2019.

Norges Bank reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Norges Bank sold 21,439 Five Prime Therapeutics, Inc. shares in Q3 2019, an estimated $129K.
Norges Bank first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 11 quarters.
Norges Bank's Five Prime Therapeutics, Inc. position peaked at $9.72M in Q3 2017.
103 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2019.

Based on Norges Bank's 13F filing for Q3 2019, filed 8 Nov 2019.